MiMedx Group, Inc. (NASDAQ:MDXG) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC raised its holdings in MiMedx Group, Inc. (NASDAQ:MDXG) by 1.6% during the third quarter, HoldingsChannel reports. The firm owned 2,794,358 shares of the company’s stock after buying an additional 44,254 shares during the period. Geode Capital Management LLC’s holdings in MiMedx Group were worth $16,518,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of MDXG. Isthmus Partners LLC raised its stake in shares of MiMedx Group by 30.4% during the second quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock worth $27,000 after purchasing an additional 91,714 shares during the last quarter. Blue Trust Inc. purchased a new position in MiMedx Group in the 3rd quarter valued at $30,000. Point72 Asset Management L.P. acquired a new position in MiMedx Group in the 2nd quarter valued at $40,000. Point72 DIFC Ltd increased its stake in MiMedx Group by 127.6% in the 3rd quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock valued at $45,000 after buying an additional 4,275 shares during the period. Finally, Entropy Technologies LP purchased a new position in MiMedx Group during the 3rd quarter worth $64,000. 79.15% of the stock is currently owned by institutional investors and hedge funds.

MiMedx Group Trading Up 0.3 %

NASDAQ:MDXG opened at $9.42 on Monday. MiMedx Group, Inc. has a 1 year low of $5.47 and a 1 year high of $10.14. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. The stock has a fifty day moving average price of $8.35 and a two-hundred day moving average price of $7.17. The stock has a market capitalization of $1.38 billion, a price-to-earnings ratio of 17.13 and a beta of 1.98.

Analyst Upgrades and Downgrades

Separately, StockNews.com lowered shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 8th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, MiMedx Group presently has a consensus rating of “Buy” and an average price target of $12.00.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.